IBI362
IBI362 is a pharmaceutical drug with 19 clinical trials. Currently 8 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 10 completed trials
Phase Distribution
Phase Distribution
6
Early Stage
4
Mid Stage
9
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
100.0%
10 of 10 finished
0.0%
0 ended early
8
trials recruiting
19
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Clinical Trials (19)
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity
A Study Comparing IBI362 vs Semaglutide in Chinese Adults With Early Type 2 Diabetes and Obesity
A Study of IBI362 in Chinese Adolescents With Obesity or Overweight
Tolerance and Pharmacokinetic/Pharmacokinetic Study of IBI362 15mg in Patients With Moderate to Severe Obesity
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
A Study of IBI362 Evaluating Weight Loss in Obese and Overweight Chinese Subjects
This is a Study to Evaluate the Pharmacokinetics and Safety of IBI362 in Chinese Adolescents With Obesity
A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）
A Study of IBI362 in Participants With Obesity or Overweight
A Study of IBI362 9 mg in Chinese Adults With Obesity
A Study of IBI362 in Participants With Type 2 Diabetes
A Study of IBI362 in Poorly Controlled Type 2 Diabetes Patients Only Through Diet and Exercise
Pharmacokinetics of IBI362 in Subjects With and Without Renal Impairment
A Study of IBI362 in Chinese Patients With Type 2 Diabetes
Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI362 in Overweight or Obesity Subjects
A Study to Evaluate the Drug-drug Interactions (DDIs) of IBI362 With Metformin, Warfarin, Atorvastatin, Digoxin in Overweight or Obese Subjects
Multiple-dose Tolerability and Pharmacokinetic of IBI362 in Chinese Patients With T2DM
All 19 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 19